Plus Therapeutics highlights Phase 1 ReSPECT-LM REYOBIQ data in AANS plenary session

PLUS THERAPEUTICS INC

PLUS THERAPEUTICS INC

PSTV

0.00
  • Plus Therapeutics highlighted Phase 1 ReSPECT-LM trial results for REYOBIQ in a plenary oral presentation already delivered May 2, 2026 at AANS 2026.
  • Data showed a favorable safety profile, signs of improved survival versus historical outcomes, meaningful anti-tumor activity, supporting continued clinical development in leptomeningeal metastases.
  • Translational findings pointed to emerging immune effects that could support future combination approaches with immunotherapies.
  • Enrollment continues in an ongoing Phase 1 multiple-dose study designed to further characterize safety across defined dosing intervals in patients with leptomeningeal metastases from any solid tumor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080730PRIMZONEFULLFEED9715960) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.